Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.
about
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TBUpdates on the risk factors for latent tuberculosis reactivation and their managementsStrategies for treating latent multiple-drug resistant tuberculosis: a decision analysisPotential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infectionCost Resulting from Anti-Tuberculosis Drug Shortages in the United States: A Hypothetical Cohort StudyImpacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in TaiwanThe societal cost of heroin use disorder in the United States.Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.Priorities for screening and treatment of latent tuberculosis infection in the United StatesQuantiFERON-TB gold in-tube implementation for latent tuberculosis diagnosis in a public health clinic: a cost-effectiveness analysis.House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study.The use of anti-tuberculosis therapy for latent TB infectionAn update on the use of rifapentine for tuberculosis therapy.A systematic review of economic evaluations of chemoprophylaxis for tuberculosis.Cost-Effectiveness of Screening and Treating Foreign-Born Students for Tuberculosis before Entering the United StatesCurrent development and future prospects in chemotherapy of tuberculosisTreatment of latent tuberculosis infection in HIV: shorter or longer?Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.A cost-benefit analysis of a proposed overseas refugee latent tuberculosis infection screening and treatment program.Cost-effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in IndiaShort-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.Update in tuberculosis 2009.Challenges and opportunities in developing novel drugs for TB.Inclusion of compliance and persistence in economic models: past, present and future.Current management options for latent tuberculosis: a review.A comparative effectiveness analysis of treatment for latent tuberculosis infection using multilevel selection models.The effectiveness of screening with interferon-gamma release assays in a university health care setting with a diverse global population.Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: a simulation study.Prophylaxis for latent tuberculosis infection prior to anti–tumor necrosis factor therapy in low-risk elderly patients with rheumatoid arthritis: a decision analysis.Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection.Moving toward tuberculosis elimination: implementation of statewide targeted tuberculin testing in Tennessee.Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to Canada.Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.Cost-effectiveness analysis of interventions for tuberculosis control: DALYs versus QALYs.Cost-effectiveness of early versus delayed antiretroviral therapy in tuberculosis patients infected with HIV in sub-Saharan Africa
P2860
Q24201325-BC81BEAB-2C2B-4D3F-9E6F-38DC10D7CF7BQ28073158-C19C769E-4A05-4A90-ADE2-CE0C097242C2Q28478920-8A00FDCB-8BA2-4346-9722-1361CF1B8743Q28479103-08593F66-E3C5-4361-942F-D371F16E941EQ28547335-1309CFC5-2DE0-4E05-9F2A-D6EA5D1488A0Q33590461-6F6FE501-84E9-4C02-96C1-CEDD556100DCQ33739154-8449CA29-D27E-49E0-988C-3EA2B73B513DQ33746114-85629FF0-6ABA-4498-A472-40628716FB17Q33895875-EAE97160-68A8-4962-8D53-9E26C2D2A334Q34518338-35CD2B37-4D0B-4D9A-9105-0A45F055C7A9Q35001048-F6634709-DE27-497A-8C9F-454A0E8C005AQ35026573-82517F9E-B77B-4155-B88F-AC83D5A15AF0Q35084363-BEBBE869-8907-4C7D-A5BA-0318C3FAA934Q35503563-62336F37-C14E-4F47-831C-30C6841C63EFQ35553230-FF639D9A-4ECA-4A4E-93FA-7C248D276F78Q35705874-DC3A4453-93D7-4CD1-8E18-17A899F2A246Q36137225-22B71831-E328-4C52-A40C-E7A0681C2AC9Q36280305-B040368D-6C4E-45EC-8EF4-A816B6E15D46Q36337142-D1D52D60-147D-4689-9C7E-C5198B754C5DQ37192288-F7C2AE61-60B1-43D1-A93A-C83E0E017F37Q37443290-D19DBF42-D20B-43C8-804D-8B4F776BFBB3Q37704062-EDAAC5FF-EEB6-473F-917C-B45D36BD58E6Q37924294-4EC855E0-83B8-4E14-9BD5-E833D66E2F52Q38048913-8B7D038D-4AEB-4807-A45B-CC71F0AC300FQ38066198-14558C78-BFA6-4574-BB52-7004A5A1CED3Q41238712-264C64ED-E991-4A8F-8D10-B818E884132FQ41593849-546A6DE5-054C-4E1B-A53D-24D4C66395DCQ41657767-2F85F6F4-6313-4A19-AAA9-3E0862797265Q42376840-F1D6CECA-593F-47BB-914A-14D154D04CACQ44381410-C7175B8C-223E-46A1-8CA9-4C20F0A20038Q45935090-BEEA449F-CBD6-4F09-B11D-021AD3CFFB07Q45988272-638B2A8A-2031-4A3C-8060-8BA978E5C3F0Q47133419-784B1483-97F6-4683-B027-9BB915717DDDQ47715774-2E7B626A-C4BD-4E02-AD0B-4B2BAF1146FFQ50682458-C4852FB8-89CC-4288-8A51-80E2FB87664BQ57990824-C705EE54-F881-4C89-BF75-D2EFB18676FB
P2860
Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Costs and cost-effectiveness o ...... latent tuberculosis infection.
@en
Costs and cost-effectiveness o ...... latent tuberculosis infection.
@nl
type
label
Costs and cost-effectiveness o ...... latent tuberculosis infection.
@en
Costs and cost-effectiveness o ...... latent tuberculosis infection.
@nl
prefLabel
Costs and cost-effectiveness o ...... latent tuberculosis infection.
@en
Costs and cost-effectiveness o ...... latent tuberculosis infection.
@nl
P2093
P2860
P1476
Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection
@en
P2093
Carol D Hamilton
David P Holland
Gillian D Sanders
P2860
P304
P356
10.1164/RCCM.200901-0153OC
P407
P577
2009-03-19T00:00:00Z